Therapy timing, patient factors, and emerging combination interventions are guiding treatment decisions in multiple myeloma and lymphoma.

24 Although the benefit of CAR T-cell therapy for multiple myeloma continues to outweigh the risk, vigilant monitoring for T-cell lymphoma should be implemented. Supported by Johnson & Johnson and ...

For 24 years, the Lymphoma, Leukemia & Myeloma Congress has stood as the premier educational conference dedicated to hematologic malignancies. Over 75 experts from around the globe gather in New ...

When experienced researcher Renato Aguilera happened across the chemical structure of a tried-and-true antimalarial drug one ...

Some forms of blood cancer, such as multiple myeloma and lymphoma, are malignant diseases that originate from immune cells, specifically lymphocytes. In recent years, CAR-T cell therapies have become ...

DelveInsight's "XPOVIO Market Size, Forecast, and Market Insight Report" highlights the details around XPOVIO, a ...

July 22, 2024 — The researchers report the ability of protein 'signatures' to predict the onset of 67 diseases including multiple myeloma, non-Hodgkin lymphoma, motor neurone disease ...

Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin’s Lymphoma; Trials ...

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

Although the cause of multiple myeloma is not known, research shows that genetic changes in the DNA of a single plasma cell ...